ArticleJournal of medical virology2021
Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome.
Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 55 citations in OpenAlex.
- Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.iScience · 2026Article
- Diagnostic Usefulness of SP-D, CCL2/MCP-1, and IL-18 in Assessing Respiratory Function and Risk of Pulmonary Fibrosis in COVID-19 Patients.International journal of molecular sciences · 2026Article
- SARS-CoV-2 innate immune recognition and implications for respiratory health.Cytokine & growth factor reviews · 2025Review
- Risk factors for invasive mold infection after COVID-19: case-control study.African health sciences · 2024Article
- Macrophage Activation Syndrome in Viral Sepsis.Viruses · 2024Review
- An antibody to IL-1 receptor 7 protects mice from LPS-induced tissue and systemic inflammation.Frontiers in immunology · 2024Article
- Article
- Is Extracorporeal Membrane Oxygenation a Panacea?The Eurasian journal of medicine · 2023Article
- Article
- Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai.Frontiers of medicine · 2023Article
- SARS-CoV-2 Spike Protein Activates Human Lung Macrophages.International journal of molecular sciences · 2023Article
- Influence of transitional care on the clinical manifestations among patients with COVID‑19: A single‑center, double‑blinded, randomized survey.Experimental and therapeutic medicine · 2023Article
- Unveiling COVID-19 Secrets: Harnessing Cytokines as Powerful Biomarkers for Diagnosis and Predicting Severity.Journal of inflammation research · 2023Article
- Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients.PloS one · 2023Article
- Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.Frontiers in immunology · 2023Review
- Review of Medical Studies on COVID-19 During the Pandemic Period.The Eurasian journal of medicine · 2022Article
- All Microbiological Aspects of SARS-CoV-2 Virus.The Eurasian journal of medicine · 2022Article
- SARS-CoV-2 Infection and Candidate Biomarkers.The Eurasian journal of medicine · 2022Article
- Nitazoxanide and COVID-19: A review.Molecular biology reports · 2022Review
- Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease.Toxins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany laboratory parameters have been associated with morbidity and mortality in SARS-CoV-2 (COVID-19), which emerged in an animal market in Wuhan, China in December 2019 and has infected over 20 million people. This study investigated the relationship between serum interleukin (IL)-18, IL-1 receptor antagonist (IL-1Ra), and alpha defensin levels and the clinical course and prognosis of COVID-19. MATERIALS AND
methodsThis study included 100 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID-19 by real-time polymerase chain reaction (PCR) of nasopharyngeal swab samples between March 24 and May 31, 2020. The control group consisted of 50 nonsymptomatic health workers with negative real-time PCR results in routine COVID-19 screening in our hospital.
resultsSerum alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in patients who developed macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) compared to patients who did not (p < .001 for all). Alpha defensin, IL-1Ra, and IL-18 levels were significantly higher in COVID-19 patients with and without MAS or ARDS when compared to the control group (p < .001 for all). When the 9 patients who died were compared with the 91 surviving patients, IL-1Ra and IL-18 levels were found to be significantly higher in the nonsurvivors (p < .001).
conclusionOur findings of correlations between alpha defensin and levels of IL-1Ra and IL-18, which were previously shown to be useful in COVID-19 treatment and follow-up, indicates that it may also be promising in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.